BRD2 and postmenopausal osteoporosis: This provoked the hypothesis that the elevated follicle-stimulating hormone (FSH) levels across the menopausal transition, rather than the decline in estrogen levels, could play a role in the development of postmenopausal osteoporosis and cardiovascular disease (CVD) for which encouraging data have been published (1–4).